Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Genie29jon Jan 25, 2023 2:39pm
191 Views
Post# 35245930

Loading up

Loading upAs we inch closer to the May judgement with Shiseido- I will be curious how that affects the stock price. I'm likely a buyer in April hoping for a positive outcome in the chance Replicel & Shiseido come to an agreement earlier and/or a favorable outcome 

I'm still a firm believer of the following in the stock price
1. The device $1-2
2. A positive outcome with Shiseido $2-3 (incremental).
3. If the data is REALLY good from Shiseido strap in, I trust the Replicel team will get investors galore wanting a piece of it. I see a  $12-15 stock price from there

many "if's" remain - but that's what you get when you invest in a pre revenue company. I trust the fact Andrew and team are feeling awfully confident given their latest investments 

but "when" it hits, better take a few days off work bc there's no chance you'll be able to concentrate on anything other than all the money you're raking in 

here's to a great 2023 for Replicel and our shares. 


<< Previous
Bullboard Posts
Next >>